Is Silence Therapeutics PLC halal to invest in?

According to Musaffa's Shariah screening methodology, Silence Therapeutics PLC (SLNCF) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Silence Therapeutics PLC a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Silence Therapeutics PLC using these criteria to determine its compliance status.

Can Muslims buy shares of Silence Therapeutics PLC?

Muslim investors may consider investing in Silence Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Silence Therapeutics PLC classified as NOT HALAL?

Musaffa determines the Shariah status of Silence Therapeutics PLC by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Silence Therapeutics PLC updated?

The Shariah compliance status of Silence Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Silence Therapeutics PLC become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Silence Therapeutics PLC?

You can check the latest Shariah compliance status of Silence Therapeutics PLC on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

SLNCF Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 10, 2026

Report Source: 2025 Annual Report

Silence Therapeutics PLC. Stock Analysis SLNCF

United States Health Care Small Cap Report: 2025 Annual

Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Key Statistics of Silence Therapeutics PLC (SLNCF)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.45$1.45

Today's Open

$1.45

Volume

4181.00

P/E Ratio (TTM)

52 Week Range

$0.97$2.63

Market Cap

336.78M

Avg. Volume

1540.60

Dividend Yield

Financial Metrics & Statements of Silence Therapeutics PLC (SLNCF)

FAQ's for Silence Therapeutics PLC (SLNCF)

According to Musaffa’s Shariah screening methodology, Silence Therapeutics PLC (SLNCF) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.